Hikma Remains Constituent of FTSE4Good Index Series

London, 10 September 2018 - Hikma Pharmaceuticals PLC (Hikma Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody’s / BB+ S&P, both stable) - the multinational generic pharmaceutical company - continues to be recognized as a constituent of the FTSE4Good Index Series for positive environmental, social and governance practices.

Press Release Responsibility 10 September 2018

“We are pleased to remain members of the FTSE4Good Sustainability Index in recognition of our commitment to globally recognised corporate responsibility standards. Since our founding 40 years ago, we have been committed to conducting our business in a responsible manner that brings about positive change in our local and global communities. We will continue to be active partners in shaping a sustainable future by engaging with our stakeholders, minimizing our environmental impact and improving transparency,” commented Hana Darwazeh Ramadan, Vice President of Corporate Communications and Corporate Responsibility at Hikma Pharmaceuticals. “We have prioritized our activities around five Sustainable Development Goals (SDGs) that most closely align with our business and social engagement strategy: Good Health and Wellbeing, Quality Education, Gender Equality, Decent Work and Economic Growth, Industry, as well as Innovation and Infrastructure,” she added.


Since 2007, Hikma has been an active member of the UN Global Compact (UNGC), the world’s largest corporate sustainability initiative mobilizing companies to do business responsibly by aligning their strategies and operations with principles on human rights, labour, environment and anti-corruption; and to take strategic actions to advance broader societal goals, such as the UN Sustainable Development Goals, with an emphasis on collaboration and innovation.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.